

ACTRIMS/LACTRIMS Teaching Course CE Information

WELCOME

The Americas Committee for Treatment and Research in Multiple Sclerosis and Latin America Committee for Treatment and Research in Multiple Sclerosis is pleased to welcome you to the ACTRIMS/LACTRIMS Teaching Course! The Teaching Course, will be held virtually on July 23—24, 2021 with education accessible until October 24, 2021.

START DATE: July 23, 2021

END DATE to CLAIM CE: October 24, 2021

EDUCATIONAL CREDITS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Interstate Postgraduate Medical Association (IPMA) and ACTRIMS. The IPMA is accredited by the ACCME to provide continuing medical education for physicians.

The Interstate Postgraduate Medical Association designates this enduring activity for a maximum of 4.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COMMERCIAL SUPPORT

None

DISCLOSURE STATEMENTS

As a provider dedicated to independent education and accredited by the ACCME, IPMA must ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All individuals with potential to influence the content of this program have disclosed all financial relationships that have occurred in the past 24 months with ineligible companies. The disclosures have been reviewed according to policy and these declarations are listed below. All individuals with potential conflicts have been contacted as needed by IPMA staff, and issues of conflict have been discussed, managed, and mitigated.

Additionally, all faculty, reviewers, and planners have been asked to disclose to learners any discussion of off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States and investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Name	Role	Relevant Financial Relationships
Lilyana Amezcua, MD, MS	Faculty	<i>Consultant, Speakers Bureau, Advisory Board:</i> Genentech, EMD Serono <i>Research:</i> Bristol Myer Squibb <i>Primary Investigator Clinical Trials:</i> EMD Serono, Genentech, Biogen
Sergio Baranzini, PhD	Faculty	No relevant relationships to disclose
Jeffrey Cohen, MD	Faculty	<i>Consultant:</i> Adamas, Atara, Bristol-Myers Squibb, Convelo, MedDay, Mylan
Fiona Costello, MD	Faculty	<i>Consultant:</i> Alexion, Frequency Therapeutics, Roche

Ari Green, MD	Faculty	<i>Consultant: Mylan, Pharmascience, Sandoz Pharma</i>
Amy Kunchok, MD	Faculty	No relevant relationships to disclose
Fernando Humuy Diaz de Bedoya, MD	Planning, Faculty	No relevant relationships to disclose
Christopher Luzzio, MD	Content Review	No relevant relationships to disclose
Heidi Ness	Planning	No relevant relationships to disclose
Jiwon Oh, MD	Faculty	<i>Research: Biogen-Idec, Roche, EMD Serono Consultant and Speakers Bureau: EMD-Serono, Sanofi-Genzyme, Biogen-Idec, Novartis, BMS, Roche</i>
Daniel Ontaneda, MD, PhD	Planning, Faculty	<i>Research: Genentech, Genzyme, Novartis Consultant: Biogen, Genentech/Roche, Genzyme, Janssen, Novartis, Merck</i>
Amanda Safa	Planning	No relevant relationships to disclose
Helen Tremlett, PhD	Faculty	No relevant relationships to disclose

PRIVACY POLICY

At IPMA, we care about providing you with tools and information to manage and protect your online privacy. IPMA retains records solely for keeping records in accordance with ACCME policies. We will not share your information with any other organizations. We will keep you informed of our CE activities. Please e-mail cmehelp@ipmameded.org if you do not want to receive any communications from us.

CE CONTACT

IPMA

PO Box 5474, Madison, WI 53705, 608.231.9045, cmehelp@ipmameded.org